STATINS The Large Prospective Studies Collaboration Group, there

STATINS
AND STROKE

 

Statins decreases strokes
of various etiology by a array of mechanisms, containing modulation of
precerebral atherothrombosis in the aorta and the carotid artery and therefore
anticipating plaque division and artery-toartery thromboembolism by restricting
coagulation at its various levels, degenerating tissue factor, innovation of
prothrombin to thrombin activity 4.

 

Vaughan et al. 5
have shown in experimental models of ischemic stroke that statin therapy decreases
the size of brain infarct and ameliorate neurologic after effect by direct
up-regulation of brain endothelial NO synthase. Additional to that, the
anti-inflammatory actions of statins probably contribute to neuroprotection and
stroke prevention.

 

The Pravastatin
Lipids and Atherosclerosis in the Carotids II (PLACII) study also established a
cognent decline in carotid intimal-medial thickness in pravastatin-treated
patients. The impact of statin treatment on aortic atherosclerosis has not been
broadly analysed 5. Decrease in stroke incidence by statins like pravastatin,
simvastatin 6 and lovastatin were also accustomed in short-term clinical
studies 7.

 

In the experiment
conducted by The Large Prospective Studies Collaboration Group, there was no correlation
between cholesterol and stroke. However, they did not categorize between
ischemic and hemorrhagic stroke 8. Cucchiara et al. 8 have shown that the
opposing effects of cholesterol on ischemic versus hemorrhagic stroke risk may
confuse efforts to compare cholesterol levels with stroke except stroke type (
i.e. hemorrhagic vs. ischemic) is taken into account.

 

In the Cholesterol
and Recurrent Events (CARE) Trial, the pravastatin group had a 31% lower
incidenceof all strokes, even though again the incidence of lethal strokes was
about the same. Summarizing, there was no increase in the rate of hemorrhagic
stroke 9.

 

On Comparisons of
statins, Laufs et al. 10 have showed the results that eshtablish that
rosuvastatin is at least as effective as simvastatin and atorvastatin and
provided better protection than lovastatin and mevastatin in the mouse middle
cerebral artery (MCA) stroke model.

BACK TO TOP